Medizinische Universität Graz - Research portal
Riedl Jakob |
Presentations at scientific and public conferences
Jonas, K; Riedl, JM; Steinlechner, SM; Moik, F; Jahn, S; Hasenleitner, S; Doleschal, B; Weiss, L; Seeber, A; Rumpold, H; Winder, T; Greil, R; Höfler, G; Gerger, A; Jost, P; Heitzer, E;
Low-level variants present a challenge in the clinical interpretation of liquid-biopsy-based comprehensive genomic profiling for patients with solid tumors
EACR Liquid Biopsies Conference; NOV 12-14, 2024; Lyon, FRANCE. 2024.
[Oral Communication]
Moik, F; Riedl, JM; Edlinger, L; Esterl, T; Hasenleithner, S; Kostmann, S; Cebular, L; Jahn, S; Kashofer, K; Zacharias, M; Hoefler, G; Heitzer, E; Gerger, A; Jost, PJ
Practice patterns and treatment outcomes of molecular tumour board (MTB)-based personalized cancer therapies: A single-center experience
ANN ONCOL. 2024; 35: S262-S263.
Doi: 10.1016/j.annonc.2024.08.130
Web of Science
FullText
FullText_MUG
Moik, F; Riedl, JM; Edlinger, L; Esterl, T; Hasenleithner, S; Kostmann, S; Cebular, L; Jahn, S; Kashofer, K; Zacharias, M; Hoefler, G; Heitzer, E; Gerger, A; Jost, PJ
122P - Practice patterns and treatment outcomes of molecular tumour board (MTB)-based personalized cancer therapies: A single-center experience
Annals of Oncology. Abstract Book of the ESMO Congress 2024, 13-17 September 2024. . 2024; 35(S2):262-263.-ESMO 2024; SEP 13-17, 2024; Barcelona, Spain.
[Poster]
FullText
Reichinger, A; Taghizadeh, H; Lentner, TK; Reimann, P; Winder, T; Kiesl, D; Romeder, F; Webersinke, G; Burghofer, J; Kirchweger, P; Riedl, JM; Prager, G; Rumpold, H; Doleschal, B
Real-world assessment of NALIRIFOX for advanced pancreatic ductal adenocarcinoma: An exploratory analysis
ANN ONCOL. 2024; 35: S929-S929.
Doi: 10.1016/j.annonc.2024.08.1583
Web of Science
FullText
FullText_MUG
Seeber, A; Huemer, F; Doleschal, B; Taghizadeh, H; Reimann, P; Moik, F; Kostmann, S; Wagner, L; Granitzer, J; Hamid, MA; Bachleitner, C; Amann, A; Wolf, D; Greil, R; Jost, PJ; Winder, T; Rumpold, H; Weiss, L; Gerger, A; Riedl, JM
Real-world effectiveness and predictive biomarker analysis of TAS-102+bevacizumab vs. regorafenib vs. TAS-102 in metastatic colorectal cancer: A multicenter cohort study
ANN ONCOL. 2024; 35: S445-S446.
Doi: 10.1016/j.annonc.2024.08.599
Web of Science
FullText
FullText_MUG
Seeber, A; Huemer, F; Doleschal, B; Taghizadeh, H; Reimann, P; Moik, F; Kostmann, S; Wagner, L; Granitzer, L; Abdel Hamid, M; Bachleitner, C; Amann, A; Wolf, D; Greil, R; Jost, PJ; Winder, T; Rumpold, H; Weiss, L; Gerger, A; Riedl, JM
530P Real-world effectiveness and predictive biomarker analysis of TAS-102+bevacizumab vs. regorafenib vs. TAS-102 in metastatic colorectal cancer: A multicenter cohort study
Annals of Oncology. Abstract Book of the ESMO Congress 2024, 13-17 September 2024. . 2024; 35(S2):445-446.-ESMO 2024; SEP 13-17, 2024; Barcelona, Spain.
[Poster]
FullText
Barth, D; Moik, F; Steinlechner, SM; Posch, F; Schlintl, V; Koch, L; John, N; Wurm, R; Pichler, M; Bauernhofer, T; Reimann, P; Wohlkönig, C; Richtig, E; Winder, T; Preusser, M; Jost, PJ; Ay, C; Gerger, A; Terbuch, A; Riedl, JM
Early kinetics of C-reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: A multi-center cohort study
ANN ONCOL. 2023; 34: S259-S259.-Annual Meeting of the European-Society-for-Medical-Oncology (ESMO); OCT 20-24, 2023; Barcelona, SPAIN.
Doi: 10.1016/j.annonc.2023.09.2917
[Poster]
Web of Science
FullText
FullText_MUG
Riedl, JM; Steinlechner, SM; Moik, F; Heitzer, E; Jahn, S; Hasenleithner, S; Doleschal, B; Weiss, L; Seeber, A; Rumpold, H; Winder, T; Greil, R; Jost, PJ; Hoefler, G; Speicher, M; Gerger, A
SOUND: A phase II trial evaluating the efficacy of molecular profiling of circulating ± tumor tissue DNA for salvagetherapy matching in patients with advanced and refractory carcinoma
ANN ONCOL. 2023; 34: S1186-S1186.-Annual Meeting of the European-Society-for-Medical-Oncology (ESMO); OCT 20-24, 2023; Barcelona, SPAIN.
Doi: 10.1016/j.annonc.2023.09.1349
[Poster]
Web of Science
FullText
FullText_MUG
Zurl, H; Embacher, S; Schollnast, H; Talakic, E; Geyer, M; Schopfer-Schwab, S; Rosenlechner, D; Scheipner, L; Jasarevic, S; Seidl, M; Altziebler, J; Mannweiler, S; Riedl, J; Schwantzer, G; Ahyai, S; Mischinger, J
Prostate tumor volume is a significant predictor to identify patients with no need for concomitant systematic biopsy in men undergoing transrectal ultrasound- MRI fusion guided biopsy of the prostate
EUR UROL. Abstracts. 2023; 83(S1):S442-S442.-38th Annual EAU Congress; MAR 10-13, 2023; Milan, ITALY.
[Poster]
Web of Science
Zurl, H; Embacher, S; Schöllnast, H; Talakic, E; Geyer, M; Schöpfer-Schwab, S; Rosenlechner, D; Scheipner, L; Jasarevic, S; Seidl, M; Altziebler, J; Simunovic, I; Bele, U; Mannweiler, S; Riedl, J; Ahyai, S; Mischinger, J
Das Prostatatumorvolumen ist ein signifikanter Prädiktor, um eine konkomitante systematische Biopsie nach transrektaler Ultraschall-MRT-Fusionsbiopsie der Prostata vermeiden zu können
DOI: 10.3205/23oegu64. 2023; -49. Tagung der Österreichischen Gesellschaft für Urologie und Andrologie und der Bayerischen Urologenvereinigung; Österreichische Gesellschaft für Urologie und Andrologie; Bayerische Urologenvereinigung; Linz, Österreich; MAI 4-6, 2023; Linz, AUSTRIA.
[Oral Communication]
FullText
Gerger, A; Riedl, J; Hasenleithner, SO; Höfler, G; Jahn, S; Esterl, T; Jost, PJ; Speicher, MR; Heitzer, E.
Identifizierung von Tumorprädispositionen im Rahmen von klinischen ctDNA-Tests
ÖGH Jahrestagung; Sep 29, 2022; Graz, AUSTRIA. 2022.
[Oral Communication]
Mischinger, J; Schoellnast, H; Zurl, H; Geyer, M; Fischereder, K; Scheipner, L; Jasarevic, S; Adelsmayr, G; Igrec, J; Fritz, G; Merdzo-Hörmann, M; Elstner, J; Schmid, J; Triebl, A; Reiter, C; Steiner, J; Rosenlechner, D; Seles, M; Pichler, G; Pichler, M; Riedl, J; Schöpfer-Schwab, S; Hutterer, G; Zigeuner, R; Augustin, H; Ahyai, S; Mannweiler, S; Fuchsjäger, M; Talakic, E
Combining targeted and systematic transrectal ultrasound guided prostate biopsy to improve verifcation and reduce misclassifcation of prostate cancer
Die Urologie 2022, 61 (Suppl 3):S159.
. 2022; -74. Kongress der Deutschen Gesellschaft für Urologie e.V.; 21.-24.09.2022; CCH Congress Center Hamburg, Deutschland.
[Oral Communication]
Mischinger, J; Schöllnast, H; Zurl, H; Geyer, M; Fischereder, K; Adelsmayr, G; Igrec, J; Fritz, GA; Merdzo-Hörmann, M; Elstner, J; Schmid, J; Triebl, A; Trimmel, V; Reiter, C; Steiner, J; Rosenlechner, D; Seles, M; Pichler, G; Pichler, M; Riedl, JM; Schöpfer-Schwab, S; Strobl, J; Hutterer, G; Zigeuner, R; Pummer, K; Augustin, H; Ahyai, S; Mannweiler, S; Fuchsjäger, M; Talakic, E
MRT gezielte Fusionsbiopsie der Prostata vs. systematische transrektale ultraschallgezielte Biopsie vs. kombiniertes Biopsieverfahren zur Detektion und korrekten Klassifikation des Prostatakarzinoms: eine retrospektive Kohortenstudie
German Medical Science GMS Publishing House; 2022. Doc22urobay38. doi: 10.3205/22urobay38. 2022; -48. Tagung der Bayerischen Urologenvereinigung und der Österreichischen Gesellschaft für Urologie und Andrologie
; 19.-21.05.2022; Inselhalle Lindau, Deutschland.
[Oral Communication]
Moik, F; Riedl, J; Barth, D; Chan, WSE; Wiedemann, S; Holler, C; Fuereder, T; Jost, P; Pabinger, I; Preusser, M; Ay, C
Early Dynamics of C-Reactive Protein Predict Risk of Venous Thromboembolism in Patients with Cancer Treated with Immune Checkpoint Inhibitors
BLOOD. 2022; 140: 1250-1251.
Doi: 10.1182/blood-2022-160087
[Oral Communication]
Web of Science
FullText
FullText_MUG
Riedl, JM; Barth, D; Steinlechner, S; Moik, F; Posch, F; Schlintl, V; Mayer, MC; Sandner, AM; Berton, F; Koch, L; John, N; Wurm, R; Pichler, M; Absenger, G; Jost, PJ; Wohlkonig, C; Richtig, E; Winder, T; Gerger, A; Terbuch, A
Early CRP Kinetics after Initiation of Immune Checkpoint Inhibitors is a predictive Biomarker for Treatment Response independent of the Tumor Antity
ONCOL RES TREAT. 2022; 45(SUPPL 2):228-228.-Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie; Okt 7-10, 2022; Wien.
[Poster]
Web of Science
Scheipl, S; Brcic, I; Moser, T; Fischerauer, S; Riedl, J; Bergovec, M; Smolle, M; Posch, F; Gerger, A; Pichler, M; Stöger, H; Leithner, A; Heitzer, E; Liegl, B; Szkandera, J
Die molekularpathologische Testung von Weichteilsarkomen mittels FoundationOne® Heme bestätigt potentielle therapeutische Targets: Ergebnisse einer monozentrischen Analyse
Abstractband 1. Österreichischer Kongress für Orthopädie & Traumatologie. 2022; -1. Österreichischer Kongress für Orthopädie & Traumatologie; 12.-14. Mai, 2022; Graz, Austria.
[Poster]
Schranz, A; Sternad, C; Mischinger, HJ; Wagner, D; Jost, PJ; Riedl, J; Wolfler, A; Pieber, T; Sourij, H; Aberer, F
Incidence of diabetes and its impact on survival after pancreatic tumor surgery - a retrospective data analysis
WIEN KLIN WOCHENSCHR. 2022; 134(SUPPL 4):258-259.-Jahrestagung der Österreichischen Diabetesgesellschaft ;
[Poster]
Web of Science
Hatzl, M; Kalmar, P; Posch, F; Riedl, JM; Beham-Schmid, C; Prochazka, K; Greinix, H; Schwarz, T; Gstettner, G; Neumeister, P; Schulz, E
BASELINE TOTAL METABOLIC TUMOR VOLUME >220CM³ AND DEAUVILLE 5-POINT SCALE OF ≥4 AFTER FOUR CYCLES OF R-CHOP ARE STRONGLY ASSOCIATED WITH INFERIOR PROGRESSION FREE SURVIVAL IN PATIENTS WITH DLBCL
EHA Library. Hatzl S. 06/09/21; 325281; EP521.. 2021; -26th Congress of the European Hematology Association; JUNE 9-17,2021; virtual .
[Poster]
FullText
Perakis, SO; Weber, S; Zhou, Q; Graf, R; Hojas, S; Riedl, JM; Gerger, A; Dandachi, N; Balic, M; Hoefler, G, Schuuring, E; Groen, HJM; Geigl, JB; Heiter, E; Speicher, MR
Harnessing circulating tumor DNA to inform clinical decisions
Festival of Genomics & Biodata 2021; JAN 26-29, 2021; London, ENGLAND. 2021.
[Onlinepräsentation]
Seles, M; Smolle, MA; Molnar, A; Riedl, JM;, Barth, DA; Terbuch, A, Rossmann, C; Mannweiler, S; Hutterer, GC, Zigeuner, R; Pummer, K; Smolle-Jüttner, FM; Lindenmann, J; Stotz, MA; gerger, A, Pichler, M; Posch, F.
Metastasektomie bei metachron metastasierten Nierenzellkarzinompatient*innen - Wer, wann & wie?
73. Kongress der Deutschen Gesellschaft für Urologie e.V.; SEp 15-18, 2021; Stuttgart, Germany. 2021.
[Oral Communication]
Smolle, MA; Herbsthofer, L; Granegger, B; Goda, M; Brcic, I; Bergovec, M; Scheipl, S; Prietl, B; Pichler, M; Gerger, A; Rossmann, C; Riedl, J; Tomberger, M; Lopez-Garcia, P; El-Heliebi, A; Leithner, A; Liegl-Atzwanger, B; Szkandera, J
Einfluss von regulatorischen T-Zellen auf die Prognose von Weichteilsarkompatienten. Retrospektive, klinisch-pathologische Studie.
Abstract-Book der Sarkomkonferenz 2021. 2021; -Sarkomkonferenz; NOV 18-20, 2021; Berlin, GERMANY.
[Oral Communication]
Barth, DA; Brenner, C; Riedl, JM;Prinz, F; Klocker, EV; Schlick, K; Kornprat, P; Lackner, K; Stöger, H; Stotz, M;Gerger, A; Pichler, M
External validation of the prognostic relevance of the Advanced Lung Cancer Infammation Index (ALI) in pancreatic cancer patients
Proceedings of the Annual Meeting of the Austrian Society of Haematology and Medical Oncology 2020. 2020; 13 (Suppl 2): 23-65.-Annual Meeting of the Austrian Society of Haematology and Medical Oncology; MAR 19-21, 2020; Vienna, AUSTRIA.
[Poster]
Gerger, A; Riedl, JM; Perakis, S; Pregartner, G; Scheipner, L; Posch, F; Groller, K; Kashofer, K; Jahn, SW; Bauernhofer, T; Pichler, M; Stoger, H; Berghold, A; Hofler, G; Speicher, M; Heitzer, E
Profiling of circulating tumour DNA for treatment selection in patients with advanced and refractory carcinoma: A prospective, two-stage phase II individualized cancer treatment trial.
ANN ONCOL. 2020; 31: S1095-S1096.-ESMO Virtual Congress; SEP 19-OCT 18, 2020; ELECTR NETWORK.
Doi: 10.1016/j.annonc.2020.08.1331
[Onlinepräsentation]
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
Perakis, SO; Weber, S; Graf, R; Zhou, Q; Riedl, JM; Dandachi, N; Balic, M; Gerger, A; Schuuring, E; Groen, HJ; Geigl, JB; Speicher, MR; Heitzer, E
Identification of actionable targets in advanced cancer patients from circulating tumor DNA using clinical decision support platforms
CANCER RES. 2020; 80(16):-AACR Annual Meeting; JUN 22-24, 2020; ELECTR NETWORK.
Doi: 10.1158/1538-7445.AM2020-1315
[Poster]
Web of Science
FullText
FullText_MUG
Perakis, SO; Weber, S; Zhou, Q; Graf, R; Hojas, S; Riedl, JM; Gerger, A; Dandachi, N; Balic, M; Hoefler, G; Schuuring, E; Groen, HJM; Geigl, JB; Heitzer, E; Speicher, MR
Liquid biopsy profiling of advanced cancer patients for clinical decision support platform analysis.
ÖGPath Frühjahrstagung 2020; SEP 11-12, 2020; Vienna, AUSTRIA. 2020.
[Oral Communication]
Posch, F; Barth, D; Brueckl, WM; Zeitler, G; Foris, V; Mollnar, S; Stotz, M; Rossmann, CH; Terbuch, A; Balic, M; Niedrist, T; Bertsch, T; Stoger, H; Pichler, M; Olschewski, H; Absenger, G; Ficker, JH; Gerger, A; Riedl, JM
C-reactive protein (CRP) levels in immune checkpoint inhibitor response and progression in advanced non-small cell lung cancer: A bi-center study.
ANN ONCOL. 2020; 31: S286-S286.-ESMO Virtual Congress; SEP 19-OCT 18, 2020; ELECTR NETWORK.
Doi: 10.1016/j.annonc.2020.08.234
[Poster]
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
Riedl, J; Perakis, S; Pregartner, G; Scheipner, L; Posch, F; Groller, K; Kashofer, K; Jahn, SW; Bauernhofer, T; Pichler, M; Stoger, H; Berghold, A; Hofler, G; Speicher, M; Heitzer, E; Gerger, A
Individualized cancer treatment based on molecular profiling of circulating tumor DNA in patients with advanced and refractory carcinoma: a prospective phase II trial.
ONCOL RES TREAT. 2020; 43(SUPPL 4):249-249.-DGHO Jahrestagung; 09.10. -11.10.2020; Basel (virtueller Kongress).
[Oral Communication]
Web of Science
Riedl, J; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, D; Schaberl-Moser, R; Stotz, M; Pichler, M; Stoger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A
FOLFIRINOX versus Gemcitabine/nab-Paclitaxel as palliative first-line treatment of advanced pancreatic cancer: An Austrian observational Tri-Center comparative effectiveness analysis.
ONCOL RES TREAT. 2020; 43(SUPPL 4):215-215.
[Poster]
Web of Science
Riedl, JM; Posch, F; Gantschnigg, A; Horvath, L; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, D; Stotz, M; Schaberl-Moser, R; Pichler, M; Stoger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A
FOLFIRINOX versus Gemcitabine/nabPaclitaxel as First-line palliative Therapy in advanced Pancreatic Cancer: a Propensity-Score Analysis.
WIEN KLIN WOCHENSCHR. Abstracts 51. Jahrestagung der Österreichischen Gesellschaft für Innere Medizin. 2020; 132(SUPPL 2):78-79.-51. Jahrestagung der Österreichischen Gesellschaft für Innere Medizin; SEP 24-26, 2020; Salzburg, AUSTRIA.
[Poster]
Web of Science
Riedl, JM; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, D; Stotz, M; Schaberl-Moser, R; Pichler, M; Stoger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A
Gemcitabine/nab-paclitaxel versus (modified) FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.
ANN ONCOL. 2020; 31: S942-S942.-ESMO Virtual Congress; SEP 19-OCT 18, 2020; ELECTR NETWORK.
Doi: 10.1016/j.annonc.2020.08.2013
[Poster]
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
Schwarzenbacher, E; Moik, F; Horvath, L; Renneberg, F; Posch, F; Barth, D; Gantschnigg, A; Schaberl-Moser, R; Pichler, M; Stotz, M; Stoger, H; Ay, C; Greil, R; Gerger, A; Djanani, A; Schlick, K; Riedl, J
Incidence, prediction and outcome of venous and arterial thromboembolism in patients with advanced pancreatic cancer treated with palliative first line chemotherapy of Gemcitabine/nab-Paclitxel or FOLFIRINOX.
ONCOL RES TREAT. 2020; 43(SUPPL 4):214-214.
[Poster]
Web of Science
Schwarzenbacher, E; Moik, F; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Barth, D; Stotz, M; Schaberl-Moser, R; Pichler, M; Ay, C; Stoger, H; Greil, R; Djanani, A; Gerger, A; Schlick, K; Riedl, JM
Patterns of venous and arterial thromboembolism in patients with advanced pancreatic cancer treated with palliative first line chemotherapy of gemcitabine/nab-paclitxel or FOLFIRINOX.
ANN ONCOL. 2020; 31: S949-S950.-ESMO Virtual Congress; SEP 19-OCT 18, 2020; ELECTR NETWORK.
Doi: 10.1016/j.annonc.2020.08.2035
[Poster]
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
Seles, M; Maisel, F; Smolle, M, Molnar, S; Riedl, JM; Barth, D; Terbuch, A; Rossman, CH; Mannweiler, S; Hutterer, GC; Zigeuner, RE; Pummer, K; Smolle-Jüttner, FM; Lindenmann, J; Stotz, M; Gerger, A; Stöger, H; Pichler, M; Posch, F
Hilfestellung zur sinnvollen Indikation der Metastasektomie bei metachron metastasierten Nierenzellkarzinompatienten.
German Medical Science. 2020; -46. Gemeinsame Tagung der Bayerischen Urologenvereinigung und der Österreichischen Gesellschaft für Urologie und Andrologie; MAY, 14-16, 2020; Nuremberg, GERMANY..
[Onlinepräsentation]
FullText
Aziz, F; Stelzl, A; Riedl, J; Smolle, M; Stojakovic, T; Posch, F; Terbuch, A; Pichler, M; Leithner, A; Stoger, H; Liegl-Atzwanger, B; Stotz, M; Gerger, A; Szkandera, J; Sourij, H
Diabetes is a predictor for survival in soft tissue sarcoma patients
WIEN KLIN WOCHENSCHR. 2019; 131(SUPPL 5):S477-S477.
[Poster]
Web of Science
Aziz, F; Stelzl, A; Riedl, JM; Smolle, MA; Stojakovic, T; Posch, F; Terbuch, A; Pichler, M; Leithner, A; Stoger, H; Liegl-Atzwanger, B; Stotz, M; Gerger, A; Szkandera, J; Sourij, H
Association of serum glucose levels with disease free survival in soft tissue sarcoma patients
DIABETOLOGIA. 2019; 62: S562-S563.-55th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD); SEP 16-20, 2019; Barcelona, SPAIN.
[Poster]
Web of Science
Barth, D; Riedl, JM; Posch, F; Smolle, MA; Kasparek, AK; Niedrist, T; Szkandera, J; Stöger, H; Pichler, M; Gerger, A; Stotz, M
Critical evaluation of platelet size as a prognostic biomarker in colorectal cancer across multiple treatment settings: a retrospective cohort study.
Proceedings of the Annual Meeting of the Austrian Society
of Haematology and Medical Oncology. 2019; -OeGHO Frühjahrstagung 2019; APR 11-13; Linz, AUSTRIA.
[Poster]
Barth, DA; Riedl, JM; Foris, V; Posch, F; Mollnar, S; Stotz, M; Pichler, M; Stoger, H; Absenger, G; Olschewski, H; Gerger, A
External validation and longitudinal extension of the LIPI (lung immune prognostic index) for immunotherapy outcomes in advanced non-small cell lung cancer
ONCOL RES TREAT. 2019; 42: 108-108.
[Poster]
Web of Science
Perakis, S; Ulz, P; Riedl, JM; Scheipner, L; Kashofer, K; Höfler, G; Geigl, JB; Speicher, MR; Heitzer, E; Gerger, A
Molecular-biological tumor profiling for drug treatment selection in patients with advanced and refractory carcinoma: A prospective, two-stage phase II individualized cancer treatment study
The Next Generation of Clinical Trials in Molecularly Driven Therapy. 2019; -AACR; MAR 29-APR 3, 2019; Atlanta, Georgia, USA.
[Oral Communication]
Perakis, SO; Ulz, P; Riedl, JM; Scheipner, L; Kashofer, K; Hoefler, G; Geigl, JB; Speicher, MR; Heitzer, E; Gerger, A
Molecular-biological tumor profiling for drug treatment selection in patients with advanced and refractory carcinoma: A prospective, two-stage Phase II individualized cancer treatment study
CANCER RES. 2019; 79(13):-Annual Meeting of the American-Association-for-Cancer-Research (AACR); MAR 29-APR 03, 2019; Atlanta, GA.
Doi: 10.1158/1538-7445.AM2019-CT130
[Poster]
Web of Science
FullText
FullText_MUG
Riedl, J; Posch, F; Prager, G; Eisterer, W; Ohler, L; Thamer, S; Wilthoner, K; Petzer, A; Pichler, P; Hubmann, E; Winder, T; Burgstaller, S; Korger, M; Andel, J; Greil, R; Pecherstorfer, M; Philipp-Abbrederis, K; Djanani, A; Gruenberger, B; Langle, F; Woll, E; Gerger, A
The AST/ALT (De Ritis) ratio predicts clinical outcome in pancreatic cancer patients treated with first-line nab-paclitaxel and gemcitabine: post-hoc analysis of an Austrian multicenter, non-interventional study
ANN ONCOL. 2019; 30: -European-Society-for-Medical-Oncology (ESMO) 21st World Congress on Gastrointestinal Cancer; JUL 03-06, 2019; Barcelona, SPAIN.
Doi: 10.1093/annonc/mdz155.285
[Poster]
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Riedl, J; Stelzl, A; Aziz, F; Smolle, M; Stojakovic, T; Posch, F; Terbuch, A; Pichler, M; Leithner, A; Stöger, H; Liegl-Atzwanger, B; Stotz, M; Gerger, A; Sourij, H; Szkandera, J
Elevated mean glucose level predicts decreased disease free survival in soft tissue sarcoma patients.
32nd Annual Meeting of the European Musculo Skeletal Oncology Society. 2019; -32nd Annual Meeting of the European Musculo Skeletal Oncology Society; MAY 15-17, 2019; Florence, ITALY .
[Poster]
FullText
Riedl, JM; Barth, D; Posch, F; Foris, V; Absenger, G; Mollnar, S; Pichler, M; Stotz, M; Stoger, H; Olschewski, H; Gerger, A
Longitudinal C-reactive protein (CRP) trajectories predict immune checkpoint inhibitor response and progression in advanced non-small cell lung cancer
ONCOL RES TREAT. 2019; 42: 115-115.
[Poster]
Web of Science
Riedl, JM; Barth, DA; Foris, V; Posch, F; Mollnar, S; Stotz, M; Pichler, M; Stoger, H; Absenger, G; Olschewski, H; Gerger, A
External validation and longitudinal extension of the LIPI (Lung Immune Prognostic Index) for immunotherapy outcomes in advanced non-small cell lung cancer
ANN ONCOL. 2019; 30: -44th Congress of the European-Society-for-Medical-Oncology (ESMO); SEP 27-OCT 01, 2019; Barcelona, SPAIN.
[Poster]
Web of Science
Riedl, JM; Stelzl, A; Aziz, F; Smolle, MA; Stojakovic, T; Posch, F; Terbuch, A; Pichler, M; Leithner, A; Stöger, H; Liegl-Atzwanger, B; Stotz,M; Gerger, A; Sourij, H; Szkandera, J
Elevated mean glucose level predicts decreased disease free survival in soft tissue sarcoma patients.
OeGHO- & AHOP-Frühjahrstagung 2019; 11.04.2019 - 13.04.2019; Linz, Austria. 2019.
[Oral Communication]
Scheipner, L; Smolle, MA; Barth, D; Posch, F; Stotz, M; Pichler, M; Stöger, H; Gerger, A; Riedl, JM
The AST/ALT ratio (de ritis) is an independent prognostic marker for disease free survival in stage II and III colorectal cancer
OeGHO- & AHOP-Frühjahrstagung 2019; 11.04.2019 - 13.04.2019; Linz, AUSTRIA. 2019.
[Oral Communication]
Smolle, MA; van de Sande, M; Callegaro, D; Wunder, J; Hayes, AJ; Leitner, L; Bergovec, M; Tunn, PU; van Praag, VM; Panotopoulos, J; Willegger, M; Windhager, R; Riedl, JM; Stotz, M; Gerger, A; Pichler, M; Stöger, H; Liegl-Atzwanger, B; Smolle, J; Leithner, A; Gronchi, A; Haas, RL; Szkandera, J
Advancing soft-tissue sarcoma aftercare using flexible parametric survival models.
Abstract Book of the 32. Annual Meeting of the European Musculoskeletal Tumour Society (EMSOS). 2019; -32. Annual Meeting of the European Musculoskeletal Tumour Society (EMSOS); MAY 15-17, 2019; Florence, ITALY.
[Oral Communication]
Smolle, MA; van de Sande, M; Callegaro, D; Wunder, J; Hayes, AJ; Leitner, L; Bergovec, M; Tunn, PU; van Praag, VM; Panotopoulos, J; Willegger, M; Windhager, R; Riedl, JM; Stotz, M; Gerger, A; Pichler, M; Stöger, H; Liegl-Atzwanger, B; Smolle, J; Leithner, A; Gronchi, A; Haas, RL; Szkandera, J
Individualising soft tissue sarcoma aftercare with flexible parametric survival modelling.
Webabstracts of the 20th General Meeting of the International Society of Limb Salvage (ISOLS). 2019; -20th General Meeting of the International Society of Limb Salvage (ISOLS); SEP 11-14, 2019; Athens, GREECE.
[Oral Communication]
Klöckl, MC; Kasparek, AK; Riedl, J; Moik ,F; Mollnar, S; Stotz, M; Szkandera, J; Terbuch, A; Gerger, A; Niedrist, T; Pichler, M; Bauernhofer T; Stöger H; Posch, F
Estimated versus measured glomerular filtration rate to
evaluate kidney function in patients with cancer undergoing
cisplatin-based chemotherapy
Oncology Research
and Treatment . 2018; 41(Suppl4):224-224.-Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie; SEP 28- OCT 2, 2018; Vienna, AUSTRIA. (ISBN: 978-3-318-06425-4 )
[Poster]
Web of Science
FullText
Leithner, A; van Praag, V; Posch, F; Bergovec, M; Leitner, L; Friesenbichler, J; Heregger, R; Smolle-Juttner, FM; Fiocco, M; van de Sande, M; Riedl, J; Pichler, M; Gerger, A; Szkandera, J; Stoger, H; Liegl-Atzwanger, B; Smolle, MA
Efficacy of metastasectomy on survival in patients with metachronous soft tissue sarcoma-metastasis: Results of a bi-centre study including 135 patients
ANN ONCOL. Abstract Book of the 43rd ESMO Congress (ESMO 2018) 19–23 October 2018, Munich, Germany. 2018; 29(S8):-43rd ESMO Congress (ESMO); OCT 19-23, 2018; Munich, GERMANY.
[Poster]
Web of Science
Nazari, PMS; Riedl, J; Preusser, M; Posch, F; Thaler, J; Marosi, C; Birner, P; Ricken, G; Hainfellner, JA; Pabinger, I; Ay, C
The combination of podoplanin expression levels and IDH1 mutation status predicts VTE risk in patients with brain tumors
THROMB RES. 2018; 164: S195-S195.-9th International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC); APR 13-15, 2018; Bergamo, ITALY.
Doi: 10.1016/j.thromres.2018.02.038
[Oral Communication]
Web of Science
FullText
FullText_MUG
Smolle, MA; Riedl, JM; Stotz, M; Pichler, M; Kashofer, K; Gerger, A
Untersuchung von 22 Genen auf das progressionsfreie Überleben von Patienten mit metastasiertem Kolorektalen Karzinom.
OeGHO- & AHOP-Frühjahrstagung 2018 ; APR 19 - 21, 2018; Villach, AUSTRIA. 2018.
[Poster]
Smolle, MA; van Praag, V; Posch, F; Bergovec; M; Leitner, L; Friesenbichler, J; Heregger, R; Smolle-Jüttner, FM; Fiocco, M; van de Sande, M; Riedl, J; Pichler, M; Gerger, A; Szkandera, J; Stöger, H; Liegl-Atzwanger, B; Leithner, A
Effect of metastasectomy on overall-survival of patients with
metachronous metastasis of STS. A bi-centre study including
135 patients.
12th Asian Pacific Musculoskeletal Tumour Society (APMSTS) Meeting; OCT 4-7, 2018; Jaipur, INDIA. 2018.
[Poster]
Smolle, MA; van Praag, VM; Posch, F; Bergovec, M; Leitner, L; Friesenbichler, J; Heregger, R; Riedl, JM; Pichler, M; Gerger, A; Szkandera, J; Stöger, H; Smolle-Jüttner, FM; Liegl-Atzwanger, B; Fiocco, M; van de Sande, MAJ; Leithner, A
Metachronous metastasis of soft tissue sarcoma: Benefit of metastasectomy. A bi-centre study.
Abstractbook of the EMSOS 2018. 2018; -31st EMSOS Meeting; MAY 9-11, 2018; Amsterdam, THE NETHERLANDS.
[Oral Communication]
Partl R, Posch F, Döller C, Riedl JM, Smolle M, Leitner L, Bergovec M, Liegl-Atzwanger B, Stotz M, Bezan A, Gerger A, Pichler M, Kapp KS, Stöger H, Leithner A, Szkandera J
Untersuchung des Benefits der adjuvanten Radiotherapie in Bezug auf Lokalkontrolle, Fernmetastasierung und Überleben bei PatientInnen mit lokalisiertem Weichteilsarkom mittels vergleichender Effektivitätsanalyse
Abstractband. 2017; -34. Jahrestagung der Österreichischen Gesellschaft für Radioonkologie, Radiobiologie und Medizinische Radiophysik ; OCT 6-7; Linz, AUSTRIA.
[Poster]
Posch, F; Silina, K; Petrausch, U; Leibl, S; Muendlein, A; Moch, H; Siebenhuener, AR; Pestalozzi, BC; Riedl, JM; Stotz, M; Szkandera, J; Stoeger, H; Pichler, M; Stupp, R; Schraml, P; Gerger, A; Winder, T;
The maturation stage of tumoral tertiary lymphoid structures to predict recurrence risk in localized colorectal cancer.
Journal of Clinical Oncology. 2017; 35 (15_suppl): e15083-e15083.-American Society of Clinical Oncology (ASCO) Annual Meeting; JUN 2-6, 2017; Chicago, IL, USA.
FullText
Posch, Florian; Riedl, Jakob; Leitner, Lukas; Liegl-Atzwanger, Bernadette; Doeller, Carmen; Bezan, Angelika; Stotz, Michael; Pichler, Martin; Gerger, Armin; Bergovec, Marko; Stoeger, Herbert; Leithner, Andreas; Szkandera, Joanna
Benefit of adjuvant radiotherapy for local control, distant metastasis, and survival outcomes in patients with localized soft tissue sarcoma: Comparative effectiveness analysis of an observational cohort study.
Proceedings of the 30th Annual Meeting of the European Musculoskeletal Oncology Society (EMSOS), A-0001. 2017; 89--30th Annual Meeting of the European Musculoskeletal Oncology Society (EMSOS); APR 26-28, 2017; Budapest, HUNGARY.
[Oral Communication]
Schmid-Zalaudek, K; Riedl, J; Rokov, M; Hilgarter, K; Mörtl, MG; Papousek, I; Weiss, E; Lessiak, V; Lackner, HK
Untersuchung der kardiovaskulären Reaktionsdynamik nach Schwangerschaftskomplikationen – eine Pilotstudie zur Eignung eines computerunterstützten kognitiven Stressparadigmas.
https://www.thieme-connect.de/products/ejournals/html/10.1055/s-0037-1607688. 2017; 221(S01):-28. Deutscher Kongress für Perinatale Medizin; NOV 30 - DEC 2, 2017; Berlin, GERMANY.
[Oral Communication]
FullText
Riedl, J; Posch, F; Stotz, M; Bezan, A; Winder, T; Schaberl-Moser, R; Pichler, M; Stoeger, H; Gerger, A
Patterns of venous thromboembolism risk in patients with localized colorectal cancer undergoing adjuvant chemotherapy or active surveillance
Annals of Oncology. 2016; -ESMO congress; Oct 7-11; Copenhagen.
[Poster]
Riedl, J; Posch, F; Stotz, M; Bezan, A; Winder, T; Schaberl-Moser, R; Pichler, M; Stoeger, H; Gerger, A
Patterns of venous thromboembolism risk in patients with localized colorectal cancer undergoing adjuvant chemotherapy or active surveillance
ANN ONCOL. 2016; 27: -41st Congress of the European-Society-for-Medical-Oncology (ESMO); OCT 07-11, 2016; Copenhagen, DENMARK.
Doi: 10.1093/annonc/mdw370.107
[Poster]
Web of Science
FullText
FullText_MUG
Silina, K; Petrausch, U; Posch, F; Leibl, S; Mündlein, A; Moch, A; Siebenhüner, A; Stupp, A; Riedl, J; Pestalozzi, BC; Schraml, P; Gerger, A; Winder, T
Comprehensive molecular and immunological analysis to assess the tumor immune contexture in stage II and III colorectal cancer
Annals of Oncology. 2016; -ESMO congress; Oct 7-11; Copenhagen.
[Poster]
Silina, K; Petrausch, U; Posch, F; Leibl, S; Mundlein, A; Moch, H; Siebenhuner, A; Stupp, R; Riedl, J; Pestalozzi, BC; Schraml, P; Gerger, A; Winder, T
Comprehensive molecular and immunological analysis to assess the tumor immune contexture in stage II and III colorectal cancer
ANN ONCOL. 2016; 27:
Doi: 10.1093/annonc/mdw393.12
Web of Science
FullText
FullText_MUG